Five things for pharma marketers to know: Tuesday, March 28, 2017



1. The FDA approved Tesaro's ovarian cancer drug, Zejula, for women with recurrent forms of the disease. The drug is expected to launch in April.

2. Sen. Claire McCaskill (D-MO) announced that the Senate Homeland Security and Governmental Affairs Committee launched an investigation into five of the largest prescription opioid manufacturers in the U.S. — Johnson & Johnson, Purdue Pharma, Insys Therapeutics, Mylan, and Depomed. The investigation will look at the role of these drugmakers in the opioid crisis.

3. Allergan and Paratek Pharmaceuticals reported that two Phase-III trials for a moderate-to-severe experimental acne drug were positive. The trial results will be used in the drug's application to the FDA.

4. Bristol-Myers Squibb, the Parker Institute for Cancer Immunotherapy, and the Cancer Research Institute announced a research collaboration to quickly begin new clinical trials. BMS will work with the two institutes to provide bioanalytical expertise and inform future drug development.

5. ICYMI: Amgen's Humira biosimilar, Amjevita, received approval to come to market in the European Union. Amjevita was approved in the U.S. in 2016 and is the first Humira biosimilar to be approved in Europe. (PMLiVE)